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Abstract 
Indirect Plasma Sterilization of Ultrasound Contrast Agent 
Lorenzo Albala 
Margaret A. Wheatley, PhD 
 
 
The ultrasound contrast agent (UCA) SE61 is composed of a sonicated 
mixture of non-ionic surfactants entrapping perfluorocarbon gas. Formulated with 
Span60 and water-soluble vitamin E, the microbubbles are a promising UCA, but 
they require a sterilization method that is unachievable by current solutions. The 
SE61 manufacturing process was improved in order to achieve safe and effective 
sterilization by introducing dielectric-barrier discharge non-thermal plasma.  
Plasma-treating phosphate-buffered saline (PBS) generates ions and 
reactive oxygen species within the liquid that disrupt microorganismal 
metabolism. This is currently the only method to obtain a sterilant solution while 
avoiding direct heat, pressure, chemicals, and radiation, or the expense of 
aseptic manufacturing methods. 3 minutes plasma treatment of PBS was chosen 
after preliminary testing, and it effectively sterilized both native and (gram-
negative and gram-positive) bacteria-inoculated samples (p = 0.0022).  
The treated and untreated samples showed no statistical significance in 
acoustic response (p >0.05 for dose-response and for half-life). Moreover, 
treated UCA retained appropriate bubble diameter (mean ± SEM: 2.52 ± 0.31µm) 
with no significant difference compared to untreated (p >0.05).  
Nile red was used to model the intercalation of drug into the hydrophobic 
portion of the microbubble shell; this hydrophobic fluorescent solvatochromic 
probe intercalated successfully into SE61, and was unaffected by plasma 
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treatment. The indirect plasma technique enters the healthcare and device 
industry as a novel sterilizing option and one that is crucial for SE61 production. 
Refining the SE61 manufacturing process can lead to enhanced diagnostic US 
and a potential drug-delivery vehicle, and it paves the way for future experiments 
and the FDA pipeline.
 1 
1. Introduction 
 The majority of currently FDA-approved sterilization techniques have 
several drawbacks, including negative alteration of material properties, such as 
molecular weight, volume, and morphology of sensitive devices. Some methods 
require high temperatures or structure-altering irradiation, while others (such as 
current plasma sterilizers) require vacuum chambers or toxic and highly reactive 
gases like formaldehyde or ethylene oxide.  
 This study deals with sterilization of an ultrasound contrast agent (UCA) 
with a delicate surfactant-stabilized shell structure, SE61. A UCA is a 
microbubble less than 6 µm in diameter that enhances an ultrasound image by 
strongly reflecting the impinging ultrasound beam back to the collecting 
transducer. Composed of Span60 and water-soluble vitamin E, the sonicated 
mixture of microbubbles can successfully enhance contrast in diagnostic and 
therapeutic ultrasound (US) imaging (1). Unfortunately, its delicate nature 
ensures that it cannot tolerate the conditions of conventional sterilization 
methods.  
The FDA identifies only two available technologies for temperature and 
moisture-sensitive medical devices: ethylene oxide (ETO) gas sterilization and 
hydrogen peroxide gas plasma sterilization (2). However, ETO is absorbed by 
many materials, is quite toxic, and requires several hours to take effect, making 
its application unsuitable for the UCA. The latter is highly oxidizing and requires a 
deep vacuum to function, which introduces another stressful pressure change to 
the manufacturing process.  
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The other sterilization alternative is the use of clean room manufacturing. 
The advantage of cleanroom use is that there is no additional sterilization step 
added to production, therefore minimizing possible losses in acoustic properties. 
A cleanroom minimizes risk of contamination from operator and environmental 
sources by controlling the level of contamination in the lab environment. 
In essence, a manufacturing process that includes the sterilization step 
with the least physical or chemical stress on the microbubble UCA is desired. It is 
impossible to traditionally sterilize the agents while maintaining the acoustic 
properties, without de novo sterilization of all components and sterile preparation 
within a clean facility. Direct application of non-thermal plasma, which does not 
have many of the aforementioned drawbacks, has already been tested for 
sterilization of Poly Lactic Acid UCA successfully (3). However, it was not 
successful with the more fragile SE61 shell composition, possibly due to the 
pressure component in the particular device used.  
The disadvantages of cleanroom use make indirect plasma an attractive 
option: It is very technically demanding, requiring compliance with cGMP and 
standards such as ISO 14644 and 14698 for airborne particulate cleanliness and 
maintenance. Also, clean facilities not only require a large initial investment for 
installation, but they can be expensive in upkeep, personnel, training, and 
regulation and compliance costs. These costs can be proscriptive to many 
smaller institutions and to those in academic settings. 
Non-thermal plasma can be generated safely at room temperature, 
atmospheric pressure, and normal atmospheric air via dielectric barrier 
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discharge. In turn, the antimicrobial properties of the plasma have been shown to 
transfer over to a liquid, such as phosphate buffered saline (PBS), which can 
retain these properties over a period of months, and inactivate a wide range of 
multi-drug resistant bacteria and fungal pathogens in planktonic and biofilm forms 
within 15 minutes (of contact with a bacterial suspension) (4). 
 The processes within the plasma that are responsible for such 
decontamination efficiency, and that can be applied to a liquid, are in part 
acidification and introduction of increased concentrations of NO2−, NO3−, and 
H2O2 (5). After treating PBS with dielectric barrier discharge, this liquid is added 
to native microbubble solution in the manufacturing process, prior to freeze-
drying. Freeze-drying has been found to yield a stable, dry product that is shelf-
stable for over 3 months (6), negating the need for immediate production prior to 
use. It hypothesized that, although produced in an unclean environment, the final 
“clinic-ready” (freeze-dried and re-filled with gas) SE61 treated with plasma-
treated PBS (PTPBS) will be sterile, without compromising its acoustic properties 
or size. 
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1.1 Overall Design Objective 
To deliver the SE61 UCA as an end-product that can mimic currently used 
commercial UCA by adapting a lab-patented manufacturing process to a novel 
microbubble formulation and sterilization procedure. 
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2. BACKGROUND 
2.1 Ultrasound 
 Ultrasound is a propagating longitudinal mechanical wave with frequency 
higher than 20 kHz. Ultrasound is mainly produced in a series of pulses rather 
than continuous waves, each pulse consisting of a certain number of cycles at a 
given frequency. In biomedical imaging applications an ultrasound pulse can 
have 2-3 cycles, while therapeutic applications can have pulse lengths of several 
thousand or more cycles.  
Ultrasound is an ideal imaging modality for (tumor) angiogenesis due to 
the universal availability of scanners, the ability to scan in real-time, and at a 
lower cost and lack of ionizing radiation compared to other imaging modalities. 
These advantages make ultrasound imaging extremely attractive compared to 
other imaging modalities in terms of its convenience, safety, and cost (7). 
At present, ultrasonography is used in conjunction with mammography for 
detecting breast cancer; in fact, US can be used to distinguish cysts from solid 
tumors and benign from malignant tumors (8). Furthermore, this and other 
advantages quickly elevated ultrasound to the recommended imaging modality 
for patients under the age of thirty (9).  
 Ultrasound is commonly generated (in biomedical applications) via the 
piezoelectric effect. The application of a potential electrical difference across a 
piezoelectric material causes a shape change proportional to the voltage. In turn, 
strain across the material results in a proportional potential difference. For this 
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reason, piezoelectric materials are used as ultrasound transducer elements in 
the conversion of an electrical signal to changing pressure and vice versa.  
 Once the transducer produces an ultrasound pressure wave that is 
directed into the body, it is reflected and absorbed in different ways by different 
tissues, generating characteristic echoes which are detected at the body surface 
(and transducer interface) from which images are constructed. Reflection from a 
given interface is dictated by the difference in acoustic impedance of the 
materials on either side of the interface.  
The density of the medium and the speed of sound in that medium define 
acoustic impedance. For this reason, dissimilar materials will result in stronger 
echoes than those from tissues of similar material, such as blood vessels and 
surrounding tissues. The wave may be totally reflected from regions containing 
air or bone—preventing imaging of underlying structure but also enhancing 
contrast of the surrounding environment. 
 
2.2 Ultrasound Contrast Agents 
In the 1960s, Gramiak and Shah confirmed that echoes could be obtained 
by injecting saline solutions into the aortic root (10). The gas bubbles in the blood 
stream that produced these strong ultrasound echoes were the result of pressure 
changes, which lead to cavitation at the tip of the catheter. Cavitation is the 
occurrence of vapor cavities in a liquid due to rapidly changing pressures (such 
as with US). When bubbles are already present in the liquid, they oscillate 
because of compressibility of their gas core and elastic properties of their shells. 
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With microbubbles produced by, for instance, hand-agitation of 
indocyanine green (11) or sucrose solutions (12), the contrast enhancement was 
extremely short-lived. The rapid dissolution of small gas bubbles (few microns in 
diameter) was resolved by the development of encapsulated gas microbubbles. 
Table 1 shows some examples of microbubble contrast agents (13, 14), some of 
which (like Albunex and Echogen) are no longer in use.  
Table 1 - Microbubble contrast agents 
Name% Shell% Gas%
Albunex% Albumin( Air(
Definity% Lipid/surfactant( Octafluoropropane(
Echovist% Galactose( Air(
Echogen% Sucrose( Dodecafluoropentane(
Imagent% Lipid/surfactant( Perfluorohexane/nitrogen(
Levovist% Galactose( Air(
Optison% Albumin( Octafluoropropane(
Sonazoid% Lipid/surfactant( Perfluorobutane(
Sonovue% Lipid( Sulfur(hexafluoride(
 
 Therefore, the gas entrapped within microbubbles dramatically enhances 
the ultrasound’s backscattered signal, increasing resolution by enhancing the 
contrast between soft tissue boundaries (e.g. myocardium, vascularity within 
tumors, etc.). In turn, the high acoustic impedance mismatch is key to enhancing 
contrast, and the ultrasound contrast agent (UCA) is stable enough to persist in 
the blood stream long enough for it to reach the region to be examined. In 
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addition, UCA must be small enough in diameter to traverse the capillary bed 
without being destroyed and without introducing any risk of causing an embolism. 
Moreover, to meet essential clinical requirements, the UCA must be non-toxic 
and biocompatible. 
2.2.1 Contrast Agents as Drug Delivery Vehicles 
The potential of loading a drug into the shell is one of the most exciting 
potential applications for UCA. Previous experiments from our lab have explored 
the combination of UCA and compounds such as hydrophobic drug Paclitaxel 
and hydrophilic drug Doxorubicin (15), and testing with Curcumin as well (16).  
The feasibility of this approach for SE61 can be explored with the use of a model 
hydrophobic drug such Nile red (17-19).  Nile red has the advantage of 
fluorescing only in a hydrophobic environment; therefore, if it is successfully 
incorporated into the SE61 shell (a hydrophobic monolayer) it will visibly 
fluoresce. However, since Nile red’s fluorescence is completely quenched in an 
aqueous environment, any Nile red that is not intercalated into the SE61 shell will 
be quenched when the UCA is reconstituted with ddH2O. 
 Indeed, ultrasound beams at sufficiently high intensity can destroy the 
microbubbles by damaging the shell integrity or by inertial cavitation. Cavitation, 
as mentioned before, is the oscillation of the microbubbles due to the acoustic 
field energy input; inertial cavitation occurs when the microbubbles implode due 
to resonant oscillations. Damage to shell integrity can be broken down into two 
mechanisms: acoustically-driven diffusion at low pressure levels and 
fragmentation at high-pressure levels (20). Acoustic pressures at or above 
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fragmentation threshold induce large-amplitude contraction and expansion of the 
UCA, damaging and de-stabilizing their shells. 
Ultrasound-mediated UCA destruction has been proposed as an essential 
mechanism in therapeutic applications, such as localized gene transfer and drug 
delivery (21).  Vigorous inertial cavitation of the UCA at the target site could also 
lend itself to ultrasound-enhanced thrombolysis (22).  
As optimized US pulse trains for quantitative imaging of blood vessel 
density and perfusion and enhanced drug delivery continue to evolve, current 
approved and trial UCA are probed for a variety of characteristics. For instance: 
transmitted US peak rarefactional pressure is altered to measure changes in 
microbubble oscillation and rate of collapse. Also, the asymmetric microbubble 
collapse is studied to visualize the fluid jets that are created (which can impinge 
on and affect the surrounding environment), and to visualize the extravasation of 
intercalated fluorescently-labeled model drugs during such collapse events (23).  
 The premise of targeted drug-delivery involves high-intensity ultrasound 
focusing on a tumor during the injection of drug-loaded UCA. When the UCA 
perfuse the vessels in the tumor and undergo inertial cavitation, they implode and 
release the drug payload locally. This approach features several advantages, 
such as reduced systemic cytotoxicity. However, at the focus of the transducer, 
increased cytotoxicity is seen for doxorubicin loaded into contrast agents when 
ultrasound is used as adjuvant (24). Others have shown that treating activated 
polymorphonuclear neutrophil (PMN) granulocytes with ultrasound in the 
presence of microbubbles can amplify apoptosis (25) as well as lactate 
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dehydrogenase leakage, causing loss of membrane integrity and even complete 
destruction at high mechanical indices. Furthermore, high intensity beams are 
proven to inhibit DNA repair and replication in cancerous cells, whereas low 
intensity beams do not have such inhibitory effects (26). 
2.2.2 Motivation for O2 Instead of Octafluoropropane 
Increased oxygenation of tumorous tissue in situ is crucial for radiation 
therapy; indeed, focused radiation therapy is frequently used in the treatment of 
breast and numerous other cancers to both eradicate the primary tumor and 
prevent metastasis.  Due to the fast growth of cancer cells (and rapid tumor mass 
expansion), angiogenesis usually falls short of cellular demand. An abnormal 
tumor microcirculation leads to an environment characterized by O2 depletion 
(hypoxia and anoxia), extracellular acidosis, high lactate levels, glucose 
deprivation, energy impoverishment, significant interstitial fluid flow, and 
interstitial hypertension. Indeed, many of these characteristics are explained by 
the fact that cancer cells are forced to up-regulate the glycolytic pathway to 
maintain a constant state of hypoxia (27, 28). Unfortunately, several studies have 
shown that this particular situation can favor both tumor progression and 
resistance to irradiation and pharmaceutical treatments (29-33). 
In turn, consequent treatment failure and a higher risk of recurrence and 
metastasis has prompted systemic solution for oxygen delivery (such as the 
hyperbaric chamber) (34, 35). However, an injectable O2 platform has the 
potential to rapidly and efficiently deliver oxygen to cancer cells immediately prior 
to radiotherapy, thereby improving cancer response to treatment. 
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Current research collaboration of our lab with Thomas Jefferson University 
Department of Radiology is based on exploiting ultrasound-induced microbubble 
destruction with O2-filled SE61 in order to deliver oxygen gas to hypoxic cells. 
This thesis describes preliminary characterization of SE61 filled with oxygen gas 
as well as qualitative performance evaluation of the same in a flow phantom 
model.  
 
 
2.3 Composition of the Proposed Platform: Vitamin E TPGS and Span60 
 The properties and advantages of surfactants used to fabricate the UCA 
are briefly described below. Our lab has published literature and holds patents 
describing the ideal molar ratios of surfactants for the preparation of 
microbubbles (36, 37). A vitamin-E conjugated PEG surfactant, water soluble 
vitamin E or D-alpha tocopheryl polyethylene glycol 1000 succinate (TPGS) has 
been recently used in our lab to (successfully) make microbubbles.  A mixture of 
TPGS and another non-ionic surfactant, Span60 (sorbitan monostearate), was 
used to stabilize gas bubbles. 
2.3.1 Span60 
An ester of sorbitan and stearic acid (Figure 1), Span60 (sorbitan 
monostearate) is a food grade emulsifier approved GRAS (generally regarded as 
safe) by the FDA (U.S.FDA No.: 21CFR172.842) for oral use and widely used in 
making bread, whipped cream, cakes, and confectionery (38). Span60 is usually 
a white solid, and is insoluble in cold water. Rat toxicity studies with 0.4-5% of 
the compound delivered through diet resulted in liver enlargement and increased 
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nephrosis only, without causing any toxicity to the rats (39). Span60 has been 
used to create micelles, niosomes (40), and organogels (intra-muscular) (41) for 
delivery of therapeutics. No adverse effects were found in a Japanese study that 
included intravenous injection (42). 
 
Figure 1 - Structure of Span60 (obtained from the Sigma-Aldrich website (Product ID: S7010)). 
2.3.2 TPGS 
D-α-tocopheryl-polyethylene-glycol-1000 succinate (TPGS) is a water-
soluble derivative of natural Vitamin E (Figure 2), which is formed by the 
esterification of lipid-soluble antioxidant Vitamin E succinate with polyethylene 
glycol (PEG). It is FDA-approved as a safe pharmaceutical adjuvant used in drug 
formulation and is a widely used food additive as well. It is a waxy, white solid 
and has the advantages of PEG and Vitamin E in applications of various drug 
delivery service, including enhanced cellular uptake of drug and extending the 
half-life of the drug in plasma (43). 
 
Figure 2 - Structure of TPGS (obtained from the Sigma-Aldrich website (Product ID: 57668)). 
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 Of particular advantage, TPGS has also served as an inhibitor of P-
glycoprotein for increasing the oral bioavailability of anticancer drugs (44). It has 
also been applied for prodrug design for enhanced chemotherapy via 
encapsulation and delivery of cytotoxic drugs such as Doxorubicin (45) and 
Paclitaxel (46). 
 2.3.3 Evolution of Our Surfactant-Stabilized UCA 
Originally, the microbubbles created in our lab were composed of Span60 
and Polysorbate (Tween) 80, another non-ionic surfactant and emulsifier (the 
UCA was called ST68). Langmuir Trough studies conducted by Singhal et al in 
our lab formed the basis of the original proposed model: a surfactant-stabilized 
microbubble with skin composition of 1.7 molecules of Span to each molecule of 
Tween (47). This ratio is probably due to the decreased Tween 80 head group 
repulsion, thanks to the smaller Span60 molecules interspersed between them.  
Because of the advantages of TPGS and its structural similarity to Tween, 
it was chosen as an alternative to Tween during formulation of microbubbles. The 
Span-TPGS microbubble was chosen for this study over the Span-Tween UCA 
because of a) its strong performance during an in vivo mouse tumor imaging 
study (1), b) preliminary data suggesting that SE61 is a very good combination 
for nano bubbles (1), which could be of interest in future studies, and c) TPGS 
has some very useful properties (see section 2.3.2), for example, it appears to 
overcome multiple drug resistance (48) and increase drug bioavailability (43, 49), 
making it very useful to study in future drug delivery applications. 
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Furthermore, the original ST68 agent created by our lab had an air core. 
Perfluorochemicals are utilized in the majority of newer agents due to their low 
solubility in blood and high vapor pressure; the filling gas imparts sufficient 
pressure to counter the sum of Laplace pressure (surface tension) and blood 
pressure (50). Indeed, much greater yields were observed with a more 
hydrophobic and less soluble gas such as octafluoropropane (51). In fact, studies 
published by our lab (in vivo mouse and rabbit experiments) have shown that 
ST68 surfactant-stabilized microbubbles have significantly superior enhancement 
compared to air, and the enhancement lasts for significantly longer than air or 
even sulfur hexafluoride-filled bubbles (52, 53).  
One of the most recent developments from our lab was the development 
of a cryoprotectant and lyophilization strategy to freeze-dry the microbubbles, 
rendering them shelf-stable (6). Another effect of the freeze-drying is the sealing 
of the vials under vacuum: this allows us to re-fill the UCA with any gas of choice 
(e.g. oxygen or PFC).  This is especially useful in the development of oxygen-
filled bubbles since a) sonication while purging with oxygen would pose a threat 
of explosion in the absence of an explosion-proof sonicator and b) as mentioned 
above, the yield would be very small.  
 
 
2.4 Non-thermal Plasma and Sterilization 
 2.4.1 The Nature of Plasma 
 Plasma is the fourth state of matter, in fact, ionized gases containing free 
charged particles like electrons and positive ions are called plasma. The most 
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widely used method for plasma generation utilizes the electrical breakdown of a 
neutral gas in the presence of an external electric field (54).  Non-thermal 
plasmas at or near atmospheric pressure have been used increasingly in the 
chemical and biological decontamination of media (55).  
In its active gaseous state it contains ions, reactive oxygen species 
(ROS), excited atoms and molecules, and UV radiation (during discharge). In 
spite of the many years plasma has been studied for this sterilization purpose, it 
has still not become widely used due to the complexity of plasma and the limited 
understanding of how it interacts with microbes. It must not be underestimated as 
a promising method for rapid and economical sterilization, as we can see in the 
literature and in this thesis: Gram-negative and Gram-positive bacteria, bacterial 
endospores, yeasts, viruses (56), and biofilms (57) are among some of the 
microorganisms susceptible to inactivation with plasma exposure. 
 2.4.2 The Use of Plasma in Sterilization Techniques 
Of particular pertinence to this study is the plasma inactivation of 
microorganisms in liquids, a well-known phenomenon (58). The technique of 
applying plasma to biological material or surface to be sterilized is known as 
dielectric-barrier discharge (FE-DBD). Acidification (mainly due to plasma-
generation of HNO2) and increased concentrations of NO2−, NO3−, and H2O2, 
have been shown to occur in plasma-treated distilled water (5, 58); effective 
decontamination has also been shown to be dependent on pH decrease (59).  
Furthermore, radicals like the superoxide anion radical (O!2-) or the 
hydroperoxyl radical HOO! have life times of a few seconds to a few minutes, 
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enabling radical-induced antibacterial activity within plasma-treated liquid if such 
liquid is added to a microorganism immediately after treatment (58). For 
example, bactericidal damage can occur as follows: the hydroperoxyl radical (O!2- 
is converted to HOO! in acidic media) can penetrate the cell membrane, convert 
back to O!2- in the neutral cytoplasm, and react with intracellular components (55, 
60, 61) 
The following figure (adapted from (58)) displays an overview of possible 
reaction channels of plasma/gas-liquid interactions: 
 
Figure 3 - Adapted from (58), possible plasma/gas-liquid reaction channels 
In fact, a combination of reaction cascades in which acid as well as 
chemical species such as NO2−, NO3−, and H2O2 are created in plasma-treated 
liquid could be responsible for the stronger antibacterial activity, especially 
compared to liquids where these components are added as chemicals, 
individually or in combinations (58). 
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N-acetyl-cysteine (NAC) treated with plasma has been shown to retain the 
antimicrobial properties for three months via delay time and for two years via 
accelerated solution aging (4). Delay time was defined as duration of time, 
starting immediately after plasma treatment until exposure of the plasma-treated 
liquid to bacteria. In the case of accelerated solution aging, the researchers in (4) 
stored plasma-treated NAC for approximately 103 days at 50°C and 254 days at 
37°C, both of which correspond to 720 days (2 years) of delay time at room 
temperature. Another conclusion from this study was that fluid-mediated plasma 
inactivates a wide range of multi-drug resistant bacteria and fungal pathogens in 
planktonic and biofilm forms with <15 minutes holding time (contact with bacterial 
suspension) (4). 
There is some other, currently unknown species (or combination of 
species) that contributes to the decontamination ability of this technique, which 
may have adverse effects on delicate structures such as surfactant-stabilized 
bubbles. This study will determine if the effects of plasma will successfully be 
integrated into the SE61 manufacturing process without disrupting the shell’s 
integrity, size, or echogenicity. The success of this research will enhance the 
realistic commercialization of UCA as delivery vehicles for many bioactives, 
including drugs, genes and bioactive gases. It will open new doors for 
manufacturing of many medical products, both delicate and robust, and other 
UCA with the incorporation of a self-sterilizing liquid to the process. 
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2.4.3 The Generation of Plasma 
 As described in a previously reported experimental setup (62), the plasma 
is generated between two electrodes: the first is a dielectric-protected powered 
electrode, and the second is a sample-carrying surface. The latter is not 
grounded and remains floating, thereby having the potential to ignite discharge 
plasma when the first electrode approaches the surface to be treated.  
When a low-frequency alternating current (120 V) is generated, the 
desired output voltage and frequency can be obtained through a step transformer 
across the interface. The indirect plasma treatment occurs when 1 mL of fluid of 
interest (placed within the second electrode), is exposed to plasma being 
discharged, with a discharge gap of 2 mm (see figure 5). 
2.4.4 Sterility Standards for an Intra-Venous Product 
 Sterility is required as stated by compendial requirements and registration 
authorities worldwide for an injectable product. The United States Pharmacopeia 
(USP) contains monographs and standards for biologic indicators of sterilization. 
A biologic indicator is a characterized preparation of specific microorganisms 
resistant to a particular sterilization process. They may be used to monitor a 
sterilization cycle and/or periodically to revalidate the process (63). Membrane 
filtration of parenteral solutions is often a decontamination solution (64), but it is 
not possible with a lyophilized powder or suspended microbubbles. 
 The USP 71 sterility test involves direct inoculation of an appropriate 
medium (e.g. Thyoglycollate, Soybean-Casein Digest) with a sample of the 
injectable product, and subsequent assessment of bacterial growth after 14 days. 
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Also, the Bacteriostasis/Fungistasis Test (B&F) validates the aforementioned 
sterility test, by determining if the test article that will be tested for sterility 
contains elements that will interfere with the growth of microorganisms (i.e. 
plasma-treated liquid ‘remnants’). Furthermore, USP sets bacterial endotoxin unit 
(i.e. synonymous with pyrogen) limits in USP 32-NF 27 (65); therefore, injections 
are not pyrogen or endotoxin free, but are limited.  
 In addition, for instance, the following standards address the general 
requirements for characterizing a sterilizing agent, requirements for sterilizing 
devices to be designated “sterile,” and the method for determination of population 
of microorganism on products, respectively: ISO 14937:2009, BS EN 556-
1:2001, and ISO 11737-1:2006. Ultimately, the final process for clinic-ready 
product should also comply with current Good Manufacturing Practices (cGMP) 
per section 21 of the Code of Federal Regulations (CFR) part 211 for 
manufacturing, packaging and storage. 
 There are many standards and guidelines in place for parenteral sterility in 
healthcare; ultimately, the reconstituted end product has to abide by mandated 
regulations and microbial limits.  
 
2.5 Encapsulated species 
2.5.1 Nile Red 
 Nile red (9-diethylamino-5H-benzo[alpha]phenoxazine-5-one) is a 
hydrophobic dye used in biological and medical research as a vital stain to 
localize and quantify lipids, to stain proteins, and to detect ligand-binding to 
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enzymes due to its fluorescent properties (Figure 4). Of particular relevance, it is 
used as a fluorescent dye probe for the study of micelles, and has been used to 
model micellar drug delivery in regard to optimized hydrophobic drug loadings 
(66).  
Nile red’s fluorescence greatly depends on the polarity of its environment 
(17, 19, 67); indeed, in aqueous media it is insoluble and its fluorescence is 
strongly quenched (18). In aqueous environments the yellow-gold fluorescence is 
detected at excitation 450-500 nm and emission is greater than 528 nm. In 
hydrophobic environments such as the wall of SE61, red fluorescence 
(excitation, 515-560 nm; emission, greater than 590 nm) is used (18). 
 
Figure 4 - Structure of Nile Red (obtained from the Sigma-Aldrich website (Product ID: N3013)). 
 Due to its high hydrophobicity, and that the color of its observed 
fluorescence depends on the polarity of its environment, Nile red is chosen as a 
model for a highly hydrophobic drug that can intercalate into the hydrophobic 
shell of our UCA. An evaluation of UCA shell fluorescence of UCA entrapping 
Nile red and treated with PTPBS and those not treated further explores the 
effects of PTPBS on the SE61 (with intercalated molecule) structure.  
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3. DESIGN ASPECTS 
 The criteria and constraints defined for this thesis project specify the 
design aspects that were employed to successfully elucidate a manufacturing 
process for sterile, shelf-stable UCA consisting of a mixed surfactant shell.  
These studies serve as a template for future investigations into the validation and 
use of PTPBS to sterilize delicate pharmaceutical products. 
 The goal is to design an SE61 UCA manufacturing process that would 
result in a sterile shelf-stable product without sacrificing acoustic properties while 
minimizing production time and cost. The final sterilized UCA should perform 
equally to the non-treated microbubbles, and should pass standard sterility 
assays including when plated on agar with no growth after 48 hours. 
 
3.1 Design Constraints and Criteria 
Constraints  
Microbubbles must have the following properties: 
- Less than 6 µm in diameter to pass unimpeded through the 
vasculature 
- No significant loss in echogenicity (dose response), compared to 
the non-treated control group. Our lab has shown that (control 
group) SE61 is a viable UCA: in the acoustic setup, >15 dB 
enhancement has translated to successful enhancement in vivo (1). 
- At least 1-minute half-life to travel through vasculature and reach the 
target after injection. By comparison, in the case of Definity® UCA the 
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product’s full prescribing information pamphlet states that: “useful 
contrast enhancement for fundamental imaging was approximately 3.4 
minutes after a 10 µL/kg bolus, and was approximately 7.1 minutes 
during the continuous infusion of 1.3 mL activated Definity® in 50 mL 
saline at a rate of 4 mL/min” (68). 
Criteria 
- Sterility, or the complete absence of viable microorganisms, including 
viruses, which could pose a risk during administration of the product 
(69, 70)  
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4. SPECIFIC AIMS 
 
The overall aim of this research was to test the hypothesis that use of 
sterilant solution produced by the interaction of Non-Thermal Plasma and PBS 
can be used to effectively sterilize SE61 surfactant bubbles while avoiding direct 
heat, pressure, chemicals, and radiation, or the expense of aseptic 
manufacturing methods that would destroy the echogenicity of the UCA. 
 
 
4.1 Specific Aims  
 The main aims of this project follow, along with the crucial design points 
that were carried out in the execution of the aims. 
4.1.1 Aim 1: Develop and perfect the SE61 manufacturing process 
• Specify correct component mixture heating times for consistent 
SE61 mixture quality 
• Determine separation funnel size specification and separation time 
so as to obtain clearest separation 
• Modify lyoprotectant molar concentration so as to maintain a 
working solution of 1:1 dilution of microbubbles in PBS, in order to 
use 1 ml native UCA/vial while accommodating for PTPBS addition 
• Create a holding ‘device’ and strategy for flash-freezing 
lyophilization vials in liquid nitrogen all at the same time and without 
risk of tipping over 
• Increase freeze-drying time from 12 hours to 24 hours 
• Determine plasma-treatment time duration and appropriate 
insertion of PTPBS addition in process flow 
• Transform all steps following freeze-dry to aseptic procedure 
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4.1.2 Aim 2: Ensure retention of UCA enhancement and appropriate size 
at the termination of the manufacturing process 
• Dose and time acoustic response curves for samples with 
octafluoropropane gas (n = 3) and O2 gas (n = 1) 
• Qualitative performance evaluation of O2-filled SE61 in flow 
phantom with clinical ultrasound scanners 
 
4.1.3 Aim 3: Confirm indirect plasma treatment as a viable sterilization 
technique for delicate UCA 
• Agar plating and microbial evaluation of samples (n = 4) 
• Qualitative evaluation of Nile Red intercalation after PTPBS 
addition/effect on ‘drug’ encapsulation 
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5. MATERIALS AND METHODS 
 
5.1 Materials 
5.1.1 Surfactants 
Two non-ionic surfactants were used for preparing the microbubbles. 
Span60 (sorbitan monostearate) (S7010, lot #010M0128) was purchased from 
Sigma Aldrich (St. Louis, MO) and used without further purification. United States 
National Formulary grade TPGS (batch# 78971100) was bought from Eastman 
and used without further purification.  
5.1.2 Other Chemicals  
Octafluropropane (99% min) was purchased from American Gas Group 
(Toledo, OH) and used after passing through a sterile 0.22 µm filter (Nalgene, 
Rochester, NY) in an aseptic (laminar flow) hood. Pure oxygen gas was 
purchased from Airgas USA, LLC. (Radnor, PA). Phosphate buffer saline (0.1M) 
was used as the buffer for preparing and testing the microbubbles after filtration 
using a 0.22 µm GV Durapore membrane filter (lot # R6AN42605) purchased 
from Millipore. Sodium chloride, potassium chloride, sodium phosphate dibasic 
and potassium phosphate monobasic were all obtained from Sigma Aldrich (St. 
Louis, MO). D-glucose (lyoprotectant agent for freeze-drying the microbubbles) 
and Nile Red was also obtained from Sigma Aldrich (St. Louis, MO). For freeze-
drying and UCA storage, 15 mL lyophilization vials obtained from West 
Pharmaceutical Services (Lionville, PA).  
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5.1.3 Non-thermal FE-DBD Plasma Generation 
The DBD-generating probe was provided by Dr. Suresh Joshi (Drexel 
University’s Hahnemann University Hospital), based on a design from Drexel 
Plasma Institute (62). The plasma generated in this manner is cold to the touch, 
and is generated at normal atmospheric conditions and in normal air (no 
separate gases used or added). The first electrode is composed of a custom-
made 34 mm x 64 mm copper electrode, the surface of which is covered with a 
(50 mm x 75 mm) 1-mm glass slide (Fischer Scientific, Inc., Pittsburgh, PA) as 
dielectric barrier. This electrode is coated with waterproof bath silicone for 
electrical insulation. A custom-built quartz liquid container holds a 1 mm liquid 
column (as the second electrode); it is capable of holding up to 1.8 mL of fluid 
(fluid contact area sizes: 32 mm x 57 mm) fixed 2 mm below the first electrode.  
 
Figure 5 - Application of fluid-mediated plasma: a schematic of 
probe and treatment (left) and a picture of the setup (right). 
5.1.4 Culture and Isolates of Bacterial Pathogens 
 E. Coli (ATCC25922) and S. Aureus (ATCC25923) strains purchased from 
American Type Culture Collection (ATCC, Manassas, VA) were maintained and 
used as overnight cultures in trypticase soy broth (TSB) for primary inoculations 
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according to the supplier’s guidelines. The known biocide agent was 70% ethyl 
alcohol. 
 
5.2 Methods 
5.2.1 Microbubble Contrast Agent Fabrication  
 UCA were manufactured via procedures published by our lab, outlined in 
United States patents (37, 71) with slight modifications (36). Appendix A 
describes, in detail, the standard operating procedure for preparing the surfactant 
microbubbles. In summary, calculated quantities of TPGS and Span 60 were 
added per 50 ml of PBS and heated. The mixture was autoclaved for 30 minutes 
in order to decrease the particle size of Span 60, followed by a cooling phase 
with continuous magnetic bar stirring to enable small particles of Span 60 to be 
formed. 
 The cooled mixture was placed in an ice bath and continuously sonicated 
for 3 minutes at 110 W using a 0.5-inch probe horn (Misonix Inc. CL4 tapped 
horn probe with 0.5″ tip, Farmingdale, NY). The solution was purged with 
octafluoropropane before and during the sonication. Microbubbles were extracted 
from the solution via gravity separation in a 250 mL glass separation funnel: 
washed 3 times with cold (4°C) PBS every 90-120 minutes using the same 
separation funnels. While in the funnel, the solution forms 3 layers (unused 
surfactant, microbubbles, and foam), of which the bottom is discarded (see figure 
16 for an photo of SE61 separation). The intermediate layer formed after the 3rd 
wash was collected as the microbubble fraction. One-mL aliquots of native 
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bubble suspension were pipetted with a pipet specifically designed for viscous 
fluids (Gilson Pipetman, Middleton, WI), into 15 mL lyophilization vials. 
5.2.2 Nile Red – Loading UCA Fabrication 
 Incorporating Nile Red in the microbubble manufacture requires a slight 
alteration of the aforementioned procedure: after the cooling phase (post-
autoclave), 0.5 mg of Nile Red was added to the solution. The solution was then 
heated once more until it began to boil, and was removed from the heat and 
allowed to cool with stirring. Sonication and subsequent steps were carried out 
as described above from this point. 
 5.2.3 Non-Thermal Indirect Plasma Treatment 
 Upon preparing the lyophilization vials with native bubble suspension 
(4.2.1), 0.5 mL of 400 mM glucose was added to each vial. The vials were placed 
on ice and transported to Hahnemann Hospital. The method for plasma 
treatment is described by Joshi et al (72) with some alterations as per Ercan et al 
(4). In essence, sterile PBS (1 mL) was pipetted into the custom-built quartz 
liquid container, and when the upper electrode was lowered into position, plasma 
was continuously generated for 3 minutes. The pulse waveform had a 5 µs pulse 
duration at 31.4 kV and 1.5 kHz where 0.29 W/cm2 power density was 
generated.  
 After plasma treatment, 0.5 mL of the PTPBS was added to each 
lyophilization vial to be sterilized. A 0.5 mL aliquot of sterile, un-treated PBS was 
added to the remaining vials to form the control group. 
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5.2.3.1 Bacterial Inoculation 
 In the experiments that featured addition of bacterial load to the samples, 
Utku Ercan (Drexel University’s Hahnemann University Hospital) prepared the 
pathogen culture: a given pathogen (10 µL inoculate) was incubated overnight in 
TSB medium (10 mL), and incubated at 37°C for 4 hours on an orbital shaker 
basic incubator. The optical density (measure of bacteria in a suspension using 
spectrophotometer) was adjusted to 0.2 at 600 nm (OD600) before use, in order to 
have uniform cell numbers each time (e.g. starting bacterial load of 
~107CFU/mL). After such preparation, the culture dilution was prepared in order 
to achieve ~1 x 103 Colony-forming Units per mL (CFU⋅mL-1) during colony count 
assay (1:1,000,000) and was mixed with the 0.5 mL of either PTPBS or sterile 
un-treated PBS (1:1). Finally, 0.5 mL of that mixture was immediately added to 
the lyophilization vials (resulting in 2 mL final total volume). 
5.2.4 Freeze-Drying and Reconstituting UCA 
 The 2 mL samples in lyophilization vials were freeze-dried as per 
procedures published by our lab (6). In brief, Fluortec© lyophilization stoppers 
were inserted into vials to the first groove (leaving a gap for air to escape). The 
samples were flash-frozen in liquid nitrogen for 5 minutes and subsequently 
freeze-dried for 24 hours on a Virtis Benchtop freeze-dryer (Gardiner, NY), on a 
two circular shelves that were previously kept at -80°C. The conditions during this 
process were -76.5°C (in the vacuum drier chamber) and 17-20 µBar, and before 
removing the samples, a piston was lowered that depressed the superior shelf, 
thereby depressing the stoppers and sealing a vacuum inside the vials.  
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 The vial of the freeze-dried (FD) mixture was further sealed by wrapping 
the stopper with paraffin tape. The microbubbles are filled with gas (PFC or 
oxygen) under an aseptic laminar flow hood by using a sterile syringe needle and 
passed through a sterile 0.22 µm Nalgene filter.  
5.2.5 Characterization of UCA 
 Samples were reconstituted with sterile ddH2O (2 ml), so that 1:1 dilution 
was maintained relative to native UCA, and they were tested for microbial load 
and acoustic properties using dose and time responses. All measurements were 
repeated 3 times with independent trials for each sample. Appendix C describes 
the settings and process in greater detail. 
  5.2.5.1 Size Distribution 
 The average diameter of the microbubbles collected was analyzed using a 
Zetasizer nano ZS (Malvern Instruments, Worcestershire, UK) in Z-average 
mode, using with dynamic light scattering technique. Cumulants analysis 
calculation is defined in ISO 13321 and ISO 22412. A 50 µL sample was 
dispersed in 950 µL PBS in tapered cuvettes for size-analysis. Appendix B 
describes the settings and process in greater detail. 
  5.2.5.2 Acoustic Testing of UCA in vitro 
 A custom-built acrylic plastic vessel with a clear acoustic window (1.5 in X 
1.5 in) was placed in a tank filled with 75 liters of ddH2O (temperature-controlled 
to 37°C) for in-vitro acoustic testing of UCA. Within the vessel, a stir-bar 
continuously stirred 50 mL of PBS at 37°C, directly in the line of sight of a single 
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Panametric (Waltham, MA) 5 MHz transducer (12.7 mm diameter, -6dB 
bandwidth of 91% and focal length of 50.8 mm). The transducer was focused 
through the acoustic window using an x-y positioning system (Edmund Scientific, 
Barrington, NJ) and a 5072 pulser-receiver (Waltham, MA) was used to generate 
acoustic pressures with a pulse repetition frequency of 100 Hz. Reflected signal 
from the UCA was detected by the same transducer and amplified 40 dB before 
being read by a digital oscilloscope (LeCroy 9350A, LeCroy Corporation, 
Chestnut Ridge, NY).  Data acquisition and processing was done on a computer 
with LabView 7.1 (National Instruments, Austin, TX). The following schematic in 
figure 6 provides a good representation of the actual setup. 
 
Figure 6 - Schematic of the acoustic testing setup, image courtesy of Nutte Tarn Teraphongphom 
 Samples were pipetted into the sample holder (filled with 50 mL PBS) with 
increments of dose as shown in table 2. Cumulative dose response was used to 
obtain maximum enhancement that is obtained from the UCA sample; this 
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approach was chosen because readings required 1 minute (i.e. 1 minute 
intervals between dose application), wherein only a small proportion of 
microbubbles is destroyed (half-life was seen to be much greater than 1 minute). 
The table below presents the dosage used. 
 For each time response, a dose was chosen on the rise of dose-
enhancement curves for each sample. This UCA volume was used to determine 
how the enhancement varies with time in the presence of an ultrasound beam. 
The values obtained were normalized with respect to initial value to compare 
approximate sample half-life value. 
Table 2 - Dose Response UCA Testing Amounts 
Dose/Trial (µL) Cum. Dose (µL) Global Cum. Dose (µL/L) 
Baseline 0 0 
2 2 40 
2 4 80 
5 9 180 
5 14 280 
5 19 380 
5 24 480 
5 29 580 
5 34 680 
5 39 780 
5 44 880 
5 49 980 
5 54 1080 
 
  5.2.5.3 Agar plating and Microbial Evaluation 
Following the freeze-drying process (see section 4.2.4), the vials were 
reconstituted with 2 mL sterile ddH2O, and 100 µL out of that volume (initial 
dilution factor of 20) was extracted to create 1:1, 1:10, and 1:100 dilutions with 
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sterile ddH2O. Consequently, volumes of 100 µL were spread on trypticase soy 
agar plates to incubate at 37°C for 24 hours. Plating was done in triplicate. After 
this incubation period, colony-forming units were counted to quantify bacterial 
load of each sample. 
5.2.5.4 Light Microscopy 
Light microscopy (Olympus IX71 fluorescence microscope) was used to a) 
obtain pictures of the microbubbles and b) assess Nile Red fluorescence for 
intercalation into shell. The images were obtained using SPOT Advanced 
software. 
5.2.6 Imaging in a Flow Phantom 
Materials and instruments used were identical to those described in (73). 
In short, ultrasound imaging was performed using a modified Logiq 9 ultrasound 
scanner (GE Healthcare, Milwaukee, WI) with two probes: 4C for deep imaging 
(footprint, 61x17 mm; bandwidth, 1.5-4.5 MHz; field of view, 58°) and 9L for 
shallow imaging (footprint, 49x9.0 mm; bandwidth, 2.5-8.0 MHz; field of view, 44 
mm). The flow phantom (model 524; ATS Laboratories, Bridgeport, CT) has a 6-
mm-diameter vessel embedded at a depth of 2 cm in urethane rubber. Contrast 
agent was circulated using a roller pump (S10K II; Sarns Inc, Ann Arbor, MI). See 
figure 6b for a schematic of the flow phantom used. 
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Figure 6b  - Schematic of flow phantom (obtained from ATS Laboratories model 750 product pamphlet) 
UCA was re-constituted with ddH2O and thoroughly mixed. Allowing the 
sample to sit with occasional shaking allows for the full volume of UCA powder to 
become suspended in solution. After sitting for approximately 15 minutes with 
occasional swirling, 0.8 mL of solution was pipetted into the flow phantom 
reservoir (saline at room temperature). The concentration of microbubble solution 
was 1.0 mL/L, and it was circulated at a rate of about 250 mL/min and the 
solution was maintained homogenous using a magnetic stirrer in the reservoir. 
Imaging was conducted at 4 and 6 MHz in B-mode/contrast harmonic mode. 
5.2.7 Statistical Analysis 
All calculations were done using Microsoft Excel from the Office 2011 
suite. Statistical analysis was done using Prism software version 6 (GraphPad). 
In order to calculate if samples were significantly different in the dose response 
and the time response test, the Kolmogorov-Smirnov test was used. This non-
parametric test was chosen because the data is not assumed to have a 
Gaussian (or any other defined) distribution, and because it tests whether or not 
the samples may reasonably be assumed to come from the same distribution 
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(with a 95% confidence interval). This type of test is ideal because treated and 
untreated samples are hypothesized to behave in the same way. 
The Kolmogorov-Smirnov test was again used in the statistical analysis of 
size distributions because the data is not assumed to have a Gaussian 
distribution, and because the Mann-Whitney test has little power when using 
small samples. Finally, Kruskal-Wallis was used for the analysis of microbial 
contamination. Kruskal-Wallis is the nonparametric version of one-way ANOVA, 
in order to compare three or more unpaired groups. 
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6. RESULTS AND DISCUSSION 
 This section contains the data obtained via the procedures outlined in 
section 4, along with statistical analyses and discussion of said data and its 
implications. 
 
6.1 Motivation 
 The motivation for the use of dielectric barrier discharge plasma 
technology stemmed from early experiments with the use of a Harrick PDC-32 G 
Plasma Sterilizer (Ithaca, NY, USA) following successful use of the technique on 
polymer UCA by other members of the lab (3). In this study, two agents were 
investigated: the SE61 agent of the current study and a very similar agent ST68, 
in which Tween 80 replaces the TPGS.  The process involved placing the UCA 
within the Harrick machine vacuum chamber, wherein direct plasma was induced 
in the presence of either nitrogen or oxygen gas for different power settings and 
durations. The plots of the dose and time response curves are as follow:  
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Figure 7 - Dose (top row) and time (bottom row) response curves of ST68 UCA subjected to direct plasma (N =1) 
 
Figure 8 - Dose (top row) and time (bottom row) response curves of SE61 UCA subjected to direct plasma (N =1) 
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As can be seen in figures 7 and 8, despite differences in degree of effect 
for the different gases combined with the two different agents, all combinations 
either affected the echogenicity and/or the stability.  Even more disappointing 
was the outcome that only approximately half of the treatments resulted in 
sterility, according to microscopy evaluation 48 hours post-treatment.   
 
6.2. Results Using PTPBS 
Use of dielectric barrier discharge plasma technology, with the assistance 
and equipment from Hahnemann University Hospital Plasma Laboratory, has 
been shown to provide a less damaging and more consistent and reliable 
decontamination method, especially by proxy (PTPBS). 
6.2.1 Establishing the Time for Treatment of PBS with DBD 
 Initially, the qualities of PBS and of the microbubbles raised some doubt 
regarding the possibility for reduced plasma efficacy. A primary concern was the 
phenomenon of acidification when a liquid is treated with plasma: would the 
phosphate-buffered saline buffer the pH drop in any way, and secondly, would 
such a change harm the delicate microbubbles? Furthermore, knowing that the 
radical species and ions created in the PBS are a part of its sterilant ability (this 
is not totally certain, though), could there be some sort of reaction with the 
antioxidant vitamin E that is an integral part of the UCA shell? The following 
experiments helped to understand if indirect plasma treatment would lead to 
sterilization, regardless of the presence of other compounds (Span60, TPGS, 
PBS, glucose). 
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 The design protocol first set out to establish the required duration of how 
long to apply dielectric barrier discharge treatment to the PBS, in order for it to 
become an antimicrobial liquid. This involved sampling the UCA after application 
of PTPBS (treated for different durations, with the same intensity); this was done 
prior to freeze-drying in order to remove a possible source of UCA destruction. 
The motivation for beginning with an echogenicity evaluation was that if all the 
microbubbles were destroyed by this form of sterilant, then there would be no 
further interest in its sterilizing ability. The following graph, figure 9, compares the 
US cumulative dose response of SE61 that had been mixed with PBS treated for 
1, 2, or 3 minute durations with an untreated PBS control. 
  
 
Figure 9  - Comparison of PTPBS treated with increasing times of discharge on UCA acoustic response. 
 N = 1, error bars = standard error about mean (SEM) 
 Given the results from the preliminary dose response pictured above, 3 
minute PTPBS was chosen as the standard plasma exposure. This was because 
of the high echogenic response that is virtually identical to the others (~20 dB). 
The decrease in response with increasing dose could be due to shadowing, 
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which could indicate that the actual microbubble density decreased in the 3-
minute group (no apparent shadowing). However, the lack of catastrophic 
acoustic failure warranted usage of the highest plasma exposure, as that would 
presumably have the most effective sterilizing potential. In addition, the sample 
size was one, again tested in triplicate (hence the SEM), as this was a 
preliminary trial. 
6.2.2 Test for Sterility 
 Armed with the previous data, the next experiment featured application of 
3 minute PTPBS to the UCA, (positive control) Ethanol (aq 70%), and (negative 
control) untreated PBS. A 100-µL volume from each vial was plated on trypticase 
soy agar plates to evaluate microbial load, and figure 10 displays the surviving 
bacteria in CFU/mL. 
 
Figure 10 - Log10 of bacterial load of UCA under different conditions.  
N = 1, error bar = SEM. 
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 The graph above shows very promising preliminary results, supporting the 
approach of exposing PBS to 3 minutes of DBD to decontaminate the UCA; indeed, 
the data shows that is as effective as suspending the microbubbles in ethanol, 
(which is an unacceptable form of sterilization since it destroys the bubbles). The 
sample size is 1 due to the preliminary nature of this investigation. 
 6.2.3 Oxygen-filled SE61, Acoustic Response 
  The application of oxygen-filled microbubbles warranted a preliminary 
evaluation of acoustic response. The transition from air to other gases in UCA 
history was due to the relatively quick diffusion and dissolution of air out of the 
bubble and into the blood, respectively. For this reason, bubbles were created as per 
the normal fabrication steps using PFC gas, except that after evacuation of 
lyophilization vials during freeze-drying, the vials were filled with oxygen gas. Time 
and dose response tests were conducted on novel oxygen-filled SE61 in order to 
ensure that it would be appropriate to perform flow phantom experiments; results 
are as shown in figure 11.  
 
Figure 11 - Dose and time response curves (left and right, respectively) for Oxygen-filled SE61, N = 1 
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 The plots in figure 11 demonstrate satisfactory echogenicity (~16 dB) and 
half-life (>14 minutes) for a microbubble that has a novel gas filling via an un-
optimized process. Size results for this UCA are 3.12 ± 0.06 µm, with a 
Polydispersity Index (PDI) of 0.89 ± 0.10. The echogenicity and size assure that it 
has a good chance to perform well in a flow phantom, and therefore in an actual 
perfusion scenario. Because this was a preliminary evaluation of oxygen as a gas 
core, the sample size for this data is 1. 
 Polydispersity Index is a dimensionless width parameter value that is also 
output by the Zetasizer, calculated from a 2-parameter fit to the cumulants analysis. 
Values greater than 0.7 indicate that the sample has a very broad size distribution 
and is probably not suitable for the dynamic light scattering technique. This 
demonstrates a drawback of the Zetasizer for measuring particle size, probably due 
to the effect of the microbubbles floating up to the surface during measurement at 
different speeds relative to their size.  
 
 
6.3 Acoustic Properties Using 3-minute PTPBS 
 The acoustic testing was conducted as per methods described in section 
4.2.5.2 and in greater detail in Appendix C. Known doses of treated samples 
were dispersed in 50 mL PBS with enhancement recording at 40 dB gain; the 
following subsections describe SE61 time and dose responses using UCA not 
treated with indirect plasma as controls. A note on testing relevant to clinical 
application: performance improves from first to subsequent repetitions of a trial, 
indicating that perhaps dry bubbles require some time (~15 minutes) to fully become 
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suspended in liquid. Maintaining the microbubbles in a cold environment (refrigerator 
at 4°C) is recommended to slow degradation. 
 6.3.1 Echogenic Dose-Response 
 The dose response curves for UCA product that has undergone the 
manufacturing process without indirect plasma effects (control) and with PTPBS 
(Plasma treated) are shown in figure 12. There is no significant difference 
between the two curves (p = 0.5696), and in fact it appears as if the control has 
slightly lower enhancement per dose. Indeed, the control has greater error at 
lower doses, which may be related to greater variety in bubble concentration and 
rate of suspension in liquid.  
 
Figure 12 - Enhancement of ultrasound signal for SE61 with and without indirect plasma sterilization.  
N = 3, error bars = SEM, p > 0.05 
 Furthermore, it is apparent that shadowing does not occur within the 
doses administered. Shadowing is the phenomenon where high concentrations 
of microbubbles completely reflect the incident ultrasound beam, yielding an 
apparent decrease in enhancement as dose continues to increase. It is similar to 
the effect of reduced visibility in fog, and can be interpreted as the maximum 
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dosage that should be administered for imaging modalities (i.e. in the above data 
it has not been reached). 
6.3.2 Echogenic Time-Response 
 The ultrasound enhancement of a single dose of microbubbles was 
measured with respect to the passing of time to determine the half-life of the 
UCA, or the time required for the enhancement to reach half of its initial value. 
This testing explores the ability of a UCA to survive exposure to ultrasound 
during vascular circulation. The dosage used for this experiment was taken from 
the linear portion of the dose-response curve, slightly prior to plateau—usually 
taking 24, 29, or 34 µL. 
  
Figure 13 – Time response for SE61 with and without indirect plasma sterilization.  
N = 3, error bars = SEM, p > 0.05 
 The LabView software program executes a reading of ultrasound 
enhancement upon initial application of microbubble dose and every subsequent 
minute. As evident in figure 13, the time response for the control and treated 
UCA are not significantly different (p = 0.9251). Furthermore, the half-life of both 
types of bubbles is longer than 15 minutes. These data makes for a great 
prediction of UCA longevity in circulation: realistically it would not experience 
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constant ultrasound activity, but the UCA would experience a variety of 
potentially disruptive forces from the pulsatile laminar flow of blood and the 
environments it flows through. 
 
6.4 Size Distribution 
 UCA microbubble sizing was determined using Malvern Nano Zetasizer. 
The settings used are described in Appendix B. The most important observation 
of the graph in figure 14 is that the PTPBS does not cause a significant change in 
the UCA compared to the control; indeed, UCA are on average smaller than 3 
microns in diameter. 
 
Figure 14 - Size distribution of treated and untreated UCA. N = 4, error bars = SEM, p > 0.05 
 The data from this assay supports that UCA can be created that satisfy a 
major constraint of UCA physical properties: UCA must be smaller than 6 
microns in diameter to safely circulate in the body. Indeed, the sterilized bubbles 
are about 2.5 microns in diameter, and are not significantly different from the 
control (p = 0.7714, exact). 
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 PDI values for the untreated and treated samples were 0.85 ± 0.11 and 
0.57 ± 0.15 (n = 4 for both), respectively. As mentioned previously in section 
5.1.1, a PDI of 0.7 or greater indicates a broad size distribution; it is important to 
note that although the size results are a reflection of a broad size distribution, it 
still provides valuable size information as well as essential comparison between 
samples. The movement of encapsulated gas suspended in liquid is probably 
more significant than Brownian motion, and it is a probable reason for error when 
using dynamic light scattering. For this reason, the use of alternative methods for 
size measurement in future studies (e.g. such as in (74), using a Coulter 
Counter) is highly recommended. 
 
 
6.5 Microbial Evaluation 
 In order to compare the bacterial load in the various UCA samples, 
bacterial survival is represented in log scale. Upon counting the amount of 
colonies formed in each trypticase soy agar plate, the value was multiplied by the 
dilution factor. For instance, since freeze-dried product is reconstituted with 2 mL 
of ddH2O, if 100 µL out of 2 mL is plated the dilution factor is 20. If the aliquot 
plated was further diluted, the dilution amount was in turn multiplied by 20. 
Typically, two dilutions were plated (up to 1:100) because the initial bacterial load 
was unknown. In inoculated samples, 104 CFU/ml of bacteria was added to the 
sample prior to addition of PTPBS; this allowed for any potential growth to occur 
during the remaining steps of manufacturing before plating of end product.  
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Figure 15 - Log10 of bacterial load of UCA under different conditions.  
N = 4, error bar = SEM, p = 0.0022 
 It is clear from figure 15 that addition of PTPBS to the manufacturing process 
wholly decontaminates the sample to which it is added, even with combined 
contamination density of initial manufacturing microbial load and inoculation of 
gram-negative or gram-positive bacteria (p = 0.0022, exact). 
 
6.6 Microscopy and Nile Red Intercalation in UCA 
 In order to ensure that PTPBS does not cause unforeseen structural 
changes to the configuration of the microbubble shell that may eliminate the 
capacity to load a hydrophobic drug, Nile Red was used as such a model. The 
fluorescent dye was added to the SE61 mixture after autoclave and before 
sonication, in a process that would allow it to become intercalated in the 
microbubble shell. 
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6.6.1 Nile Red as a Hydrophobic Drug Model 
 The goal of this test was to visualize (qualitatively), through optical 
fluorescence microscopy, that the red light emitted from the Nile Red was a) in 
the shells of the control (treated with regular PBS) microbubble, and b) that the 
UCA with PTPBS also had comparable Nile Red placement and emission. 
 
Figure 16 - Light fluorescence microscopy (40x, with 1.6x eyepiece/camera magnification) of  
SE61 w/ Nile Red intercalated. Size bar = 5 microns 
 If Nile Red were not intercalated within the shell of the UCA, its emission 
would be immediately quenched since the bubbles are suspended in aqueous 
media. The two images above provide qualitative assurance that a hydrophobic 
compound can be loaded into SE61, and that it is not removed or noticeably 
affected by PTPBS. 
 
6.7 Imaging in Flow Phantom 
 A flow phantom (see section 5.2.6 for equipment details) was used to 
visualize the UCA, which were filled with oxygen gas instead of PFC gas, in a 
simulated arterial passage using a clinical ultrasound machine and transducers. 
The following images were extracted from the machine during imaging: 
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Figure 17 - Images extracted from clinical ultrasound machines. A and B: baseline and 3 minutes post-injection, 
6 MHz linear transducer, sagittal view. C: 5 minutes post-injection, 4 MHz curvilinear transducer, sagittal view. 
D: 15 minutes post-injection, 6 MHz linear transducer, transverse view. 
 Figures 17.A-Di show the vessel in B-mode, while 17.A-Dii is contrast 
mode, which more clearly displays the enhancement from the UCA. SE61 filled 
with oxygen gas show substantial echogenicity, and are echogenic well beyond 
10 minutes post-injection. 
  
Ai Aii 
Bi 
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6.8 Final Manufacturing Process 
 The following graphic displays the final process, including tests that were run 
during this work (see Appendices A-D for full manufacturing and testing 
procedure). 
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7. CONCLUSIONS AND FUTURE RECOMMENDATIONS 
 
7.1 Conclusions and Contributions to Science 
 The culmination of this research work is the production of a sterile, shelf-
stable ultrasound contrast agent that is a great candidate as a commercial UCA 
and for future targeted (drug, oxygen, other) delivery. The manufacturing process 
produced herein melds patented surfactant-stabilized microbubble manufacturing 
with indirect plasma sterilization, providing an inexpensive and effective 
approach for a final market-ready product. 
 The design aims were thoroughly investigated and successfully achieved: 
the Final Manufacturing Process (6.8) and the attached SOPs (Appendix A-D) 
allow future researchers to create a UCA that satisfies all the constraints and 
criteria that were described in section 3.1. 
 Ultrasound enhancement (dose and time-responses) and UCA size are 
not significantly changed with indirect plasma sterilization, and the potential for 
drug loading is not inhibited by this treatment. In other words, indirect plasma 
treatment results in total sterilization without compromising UCA functionality. 
The successful manufacturing process and promising UCA response supports 
feasibility for plasma as an alternative sterilization modality. 
  
7.2 Future Recommendations 
 At this point, SE61 created as per the manufacturing process developed 
and refined over the course of this thesis is a potential candidate for animal 
testing and FDA validation for entry into the contrast agent market. Drug loading 
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and payload evaluation is the next step to ascertain potential UCA-drug 
combinations, followed by in vivo animal studies. In addition, more studies can be 
conducted to solidify an understanding of SE61, for example: alternative 
microbubble sizing, population density, and even modeling of shell surface 
tension and temporal evolution of microbubble size as described in (74). 
 The ease of PTPBS application and DBD make this sterilizing modality a 
very attractive option for other delicate tools, agents, and devices. It will surely 
continue to be a topic of intense research, especially until the mechanism for 
sterilization and the transfer of sterilization potential to a liquid is more clearly 
understood. 
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Appendix 
 
 
 
Appendix A: A Standard Procedure to Produce SE61 
 
1. To a clean beaker, add 1.5g of sodium chloride, 1.464 g of Span 60, and 
1.288 g of TPGS in 50mL of PBS, and a stirrer bar. 
• This will result in 50 mL of solution, can multiply each ingredient by 
2 to get 100 mL, and so on. 
• The smaller the pieces of TPGS, the less time for it to melt 
 
2. Cover this beaker with aluminum foil and put a piece of “autoclave” tape 
on the foil. 
 
3. Heat/stir this beaker (not too hot) until you see it begin boiling.   
 
4. Let the solution boil until Span and TPGS completely melt/dissolve, 
approximately 1-2 hours. 
 
5. Autoclave for approximately 35 min. This reduces Span60 particle size.  
*** 
 
6. If conjugating/intercalating Nile Red/other compound: 
 
a. After the mixture has been autoclaved and cooled down to room 
temperature, add 0.5mg of Nile Red.   
 
b. Heat/stir this mixture (not too hot) until you see it begin boiling.  At 
this point, remove the beaker from the heat. 
 
7. Let the mixture cool to room temperature for 30-45 minutes while stirring 
constantly.   
 
-Possible to stop here, put mixture in 4°C fridge, and continue another day- 
 
8. While the mixture is cooling, it would be a good idea to put separation 
funnels (needed later on) in the fridge so that they will be cold.   
• Use the 250 mL separation funnel, better separation/results 
• Need 50 mL per funnel, so use as many as you want/need 
 
9. After the mixture has cooled to room temperature, prepare for sonication.  
(MAKE SURE TO REMOVE MAGNETIC STIRRER BAR) 
• Transfer 50 mL of solution to a 150 mL (tall) beaker and set up in 
ice bath  
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10. Purge the mixture with PFC gas until bubbles cover the solution before 
sonication (about 15 s @ 15 ml/min). 
• NOTE: When purging with gas, the tip that supplies the gas WILL 
be in the solution.  When sonicating, the tip supplying the gas will 
NOT be in the solution, only the sonication probe will be 
submerged.  (Make sure to wear protective headphones) 
 
11.  The solution is sonicated (Misonix Inc. CL4 tapped horn probe with 0.5” 
tip, Farmingdale, NY) at 110W for 3 minutes in ice bath under a steady 
stream of PFC gas.   
 
12.  When sonication is complete, remove the beaker and retrieve the cold 
separation funnels from the fridge.  Empty the contents of the beaker into 
one of the separation funnels (make sure the bottom is closed).   
 
13. Wash the beaker with 20mL cold membrane-filtered PBS and add 30mL of 
cold PBS to the separation funnel. Place it in the fridge for 1.5-2 hours  
 
• Separation becomes clear after an extensive period of time, 
sometimes it is a little more than 1 hour, usually 1.5-2 hours. 
Easiest to see demarcation with 250 mL separation funnel, check 
occasionally 
 
 
Figure 18 - Separation funnels with SE61 (loaded with Nile Red), can clearly see separation.  
Removing bottom layer in left funnel 
14. After the allotted time, remove the separation funnel from the fridge and 
discard the bottom layer (when using 50 mL of original solution, discard 
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volume ranges 40-70 mL). Add another 50 mL of cold PBS to the funnel 
and replace in fridge. Time separation, same as before (maybe a little 
less). 
 
15. After the allotted time, repeat 13. 
 
 
16. After the allotted time (3 separations total), discard the bottom layer and 
collect the second layer, which contains the microbubbles of appropriate 
size. 
 
17. At this point can directly perform acoustic testing on native bubbles 
suspended in PBS, or pipet 1 mL in lyophilization vials with 0.5 mL 400 
mM glucose lyoprotectant and 0.5 mL plasma-treated PBS to prepare for 
freeze-drying. 
 
• Working solution is 1:1 microbubbles in membrane-filtered PBS 
 
*** Autoclave:  Take out the inner part of the autoclave and measure the water 
level.  The water level should be between the 2-2.5 inch mark, if not, adjust the 
water level accordingly.  Turn the heat to maximum so that the water begins 
heating.  After putting in the beakers, put the top back on the autoclave and 
screw all the knobs in place. Wait until seeing the water boil then close a 
ventilation valve. Wait until the pressure inside reaches the green zone, adjust 
the heat to 4, and count 35 minutes from there.  Make sure to release pressure 
accordingly using the control valve.  Also, be sure to wear the mitts to avoid 
causing injury.    
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Appendix B: Size Analysis SOP 
 
1. Size analysis was done using Zetasizer nano ZS (Malvern Inst., 
Worcestershire, UK).  
 
2. 50 µl of 1:1 diluted microbubbles is pipetted at the bottom of a tapered 
cuvette, followed by 950 µl membrane-filtered cold PBS. The cuvette is 
then placed in the slot of the instrument.  
 
3. The appropriate Measurement SOP was chosen from the dropdown in the 
Zeta-sizer software GUI and the measurement taken three times.  
 
• Used ST68CS measurement SOP: Material (RI: 1.300, absorption: 
0.01), Dispersant (RI: 1.330, Viscosity: 0.8872 cP, Temp: 25°C) 
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Appendix C: Enhancement (Dose and Time Response) SOP 
 
1. Initial set-up for the acoustic testing of microbubbles is to set the function 
generator to PRF to 100 Hz, energy to 1, and damping to 3. A 5072 
pulser-receiver (Waltham, MA) is used to generate acoustic pressures 
with a pulse repetition frequency (prf) of 100 Hz. Oscilloscope (Lecroy 
9350 A, Chestnut Ridge, NY) is set to 1 µs and 100 mV.  
 
2. Fill the inner vessel with 50 ml of 37°C membrane-filtered PBS and add 
stir bar. The transducer is focused through the transparent window until a 
signal is seen at 20 dB gain for 20 µsec delay.  
 
3. Using a 5 MHz transducer, set the gain initially to 20 dB and find the 
optimal angle and distance for transducer. The cover of the tank was fitted 
with an x–y positioning system (Edmund Scientific, Barrington, NJ) to 
mount and position the ultrasonic transducers. Use 40 dB gain to measure  
 
• Signal should have peaks touching the top and bottom edges of the 
screen between the 1st and 2nd horizontal tick-marks 
 
4. Create a folder with sample details to save the data. Open the LabVIEW 
(National Instruments, Austin, TX) program in the computer to record data 
(Ultrasound folder->main program->main ultrasound program.vi). Set Cur 
Dir to folder created.  
 
5. Make the baseline for the sample and press acquire. Wait until the saving 
is done (it is advisable that the voltage reading is less than 4 mV for the 
baseline).  
 
6. Change the sample name to dose 1 (program will automatically increase 
dose name number after each reading). Add sample to the sample 
chamber and press acquire. Wait until the saving is done and immediately 
add the next dose and press aquire.  
 
7. Repeat this until the desired total dose is obtained (in most cases, this is 
the dose where shadowing effect begins to affect enhancement).Export 
the data (calculated and raw) to folder created for the sample in step 4 
and save.  
 
8. For the time response, select a dose on the rise of the dose response 
curve, before the peak is reached, and set the time response to 15 min 
(set interval to 1 min between samples).  
 
9. Make baseline again and save in a new folder. Add the dose chosen from 
previous step and press acquire. Export the data to the folder as 
mentioned in step 9.   
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Appendix D: Freeze-drying SOP 
 
1. Follow SOP for creating SE61 microbubbles until step 15, pipet 1 mL from 
acquired bottom layer in lyophilization vials with 0.5 mL 400 mM glucose 
lyoprotectant and 0.5 mL plasma-treated PBS to prepare for freeze-drying. 
 
2. Quick freeze in liquid nitrogen for 5 minutes. Place lyophilization septum 
stoppers (West Pharmaceutical Services) on vials to first groove and let sit 
at -80°C until ready or place right onto previously chilled (-80°C) lyophilizer 
shelf.  
 
3. Freeze dry for 24 hours. While the vials are still under vacuum lower 
piston on the lyophilizer to close the septum stoppers onto the vials. Raise 
piston and slowly release the vacuum. 
 
--Perform the following steps as per aseptic procedure-- 
 
4. Wrap a piece of parafilm around the seam where the septum stopper 
meets the vial to prevent leaks. Repeat for each vial. Place vials under 
laminar flow hood. 
 
5. While in aseptic laminar flow hood, add PFC or O2 gas into the vials by 
using a sterile syringe needle injected through the rubber septum. Gas is 
passed through a sterile 0.22 µm Nalgene filter. Use a 25.5G needle and 
allow gas to flow at 6 (50 ml/min) initially and then lower to 4 (20 ml/min) 
until full minus the reconstitution volume (volume of bubbles originally 
added). 
 
• If don’t know flow rate, inject with gas until 2-3 seconds after the 
powder stops flying around inside vial  
 
6. Reconstitute just prior to use by injecting a volume of ddH2O equal to the 
original sample volume prior to freeze-drying (2 mL) and shake until 
particles are suspended. 
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